文献速递免疫规划慢病防控与筛查

重组卡介苗用于结核病与膀胱癌的研发进展

Recombinant BCGs for tuberculosis and bladder cancer.
PubMed 文献 · Vaccine · 2021-09-27

卡介苗(BCG)是唯一获批的结核病疫苗,对儿童结核死亡有重要贡献,但对成人肺结核保护不完全,其 efficacy 仍存争议。综述讨论通过基因改造BCG、改变给药途径或复种以增强结核保护,并指出膀胱内BCG是唯一获批的微生物免疫疗法,为未治疗的非肌层浸润性膀胱癌一线治疗,但近三分之一患者无应答或复发,亟需改进的膀胱内疗法。

要点

  • BCG仍是唯一获批结核疫苗,但成人肺结核保护不完全。
  • 基因改造、改变途径或复种BCG可能提升结核保护。
  • 膀胱内BCG为NMIBC一线微生物免疫治疗,近1/3患者无应答或复发。

核心结论

  • 基因改造的第二代BCG在结核疫苗和NMIBC抗肿瘤佐剂治疗中均显示前景。

研究设计与样本

  • 综述,讨论第二代基因改造BCG候选疫苗作为结核疫苗及NMIBC抗肿瘤佐剂疗法的开发。

主要发现

  • 基因改造BCG、改变给药途径或复种可提供更好的结核保护。
  • 膀胱内BCG是唯一获批的微生物免疫治疗,为未治疗NMIBC的一线治疗。
  • 近三分之一NMIBC患者对BCG无应答或出现肿瘤复发,疾病进展风险更高。

关键数值与推荐

  • BCG是唯一获批的人用结核疫苗。
  • 膀胱内BCG为未治疗非肌层浸润性膀胱癌(NMIBC)的一线治疗。
  • 近三分之一NMIBC患者BCG无应答或复发。

临床怎么用

  • 关注基因改造BCG作为结核疫苗和NMIBC膀胱内治疗的临床开发进展。
  • 对NMIBC患者需评估BCG无应答或复发风险。

局限性

  • 综述未报告具体研究样本量、效应量或统计阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bacillus Calmette-Guérin (BCG) vaccine is an attenuated live strain of Mycobacterium bovis. It may be the most widely used vaccine in human history and is the only licensed human tuberculosis (TB) vaccine available. Despite its excellent safety history, a century of use in global vaccination programs, and its significant contribution to reducing TB mortality among children, the efficacy of BCG continues to be disputed due to its incomplete protection against pulmonary TB in adults. Still vaccines offer the best chance to contain the ongoing spread of multi-drug resistance TB and disease dissemination. The development of improved vaccines against TB therefore remains a high global priority. Interestingly, recent studies indicate that genetically modified BCG, or administration of existing BCG through alternate routes, or revaccination, offers improved protection, suggesting that BCG is well poised to make a comeback. Intravesical BCG is also the only approved microbial immunotherapy for any form of cancer, and is the first-line therapy for treatment-naïve non-muscle invasive bladder cancer (NMBIC), which represents a majority of the new bladder cancer cases diagnosed. However, almost a third of patients with NMIBC are either BCG unresponsive or have tumor recurrence, leading to a higher risk of disease progression. With very few advances in intravesical therapy over the past two decades for early-stage disease, and a limited pipeline of therapeutics in Phase 3 or late Phase 2 development, there is a major unmet need for improved intravesical therapies for NMIBC. Indeed, genetically modified candidate BCG vaccines engineered to express molecules that confer stronger protection against pulmonary TB or induce potent anti-tumor immunity in NMIBC have shown promise in both pre-clinical and clinical settings. This review discusses the development of second generation, genetically modified BCG candidates as TB vaccines and as anti-tumor adjuvant therapy for NMIBC.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Singh AK, Srikrishna G, Bivalacqua TJ, et al. Recombinant BCGs for tuberculosis and bladder cancer. Vaccine. 2021. PMID: 34593271. doi:10.1016/j.vaccine.2021.09.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。